- Home
- VRCA vs BOLD Comparison
VRCA vs BOLD Comparison
Compare VRCA & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- BOLD
- Stock Information
- Founded
- VRCA 2013
- BOLD 2018
- Country
- VRCA United States
- BOLD United States
- Employees
- VRCA N/A
- BOLD N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- VRCA Health Care
- BOLD
- Exchange
- VRCA Nasdaq
- BOLD Nasdaq
- Market Cap
- VRCA 32.7M
- BOLD 33.4M
- IPO Year
- VRCA 2018
- BOLD 2024
- Fundamental
- Price
- VRCA $3.77
- BOLD $1.24
- Analyst Decision
- VRCA Hold
- BOLD Buy
- Analyst Count
- VRCA 2
- BOLD 4
- Target Price
- VRCA N/A
- BOLD $4.00
- AVG Volume (30 Days)
- VRCA 247.5K
- BOLD 133.2K
- Earning Date
- VRCA 11-06-2025
- BOLD 11-05-2025
- Dividend Yield
- VRCA N/A
- BOLD N/A
- EPS Growth
- VRCA N/A
- BOLD N/A
- EPS
- VRCA N/A
- BOLD N/A
- Revenue
- VRCA $14,704,000.00
- BOLD N/A
- Revenue This Year
- VRCA $332.45
- BOLD N/A
- Revenue Next Year
- VRCA $12.85
- BOLD N/A
- P/E Ratio
- VRCA N/A
- BOLD N/A
- Revenue Growth
- VRCA 5.72
- BOLD N/A
- 52 Week Low
- VRCA $3.28
- BOLD $1.00
- 52 Week High
- VRCA $13.60
- BOLD $3.75
- Technical
- Relative Strength Index (RSI)
- VRCA 44.18
- BOLD 43.03
- Support Level
- VRCA $3.37
- BOLD $1.15
- Resistance Level
- VRCA $3.99
- BOLD $1.52
- Average True Range (ATR)
- VRCA 0.25
- BOLD 0.06
- MACD
- VRCA 0.03
- BOLD -0.03
- Stochastic Oscillator
- VRCA 45.12
- BOLD 27.03
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.